Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease

Neuroscience Letters

Volumn 570, Issue , 2014, Pages 81-85

  Schmidt, Frank Martin ^a   Mergl, Roland ^a   Stach, Barbara ^a   Jahn, Ina ^a   Gertz, Hermann Josef ^a   Schönknecht, Peter ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Major depressive disorder; Neuron specific enolase; NSE; Tau

Indexed keywords

NEURON SPECIFIC ENOLASE; TAU PROTEIN; BIOLOGICAL MARKER; ENOLASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; CEREBROSPINAL FLUID; MIDDLE AGED;

ADULT; AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; TAU PROTEINS;

EID: 84899698364     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.04.007     Document Type: Article

References (34)

1. Roe C.M., Fagan A.M., Williams M.M., Ghoshal N., Aeschleman M., Grant E.A., Marcus D.S., Mintun M.A., Holtzman D.M., Morris J.C. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 2011, 76:501-510.
2. Hertze J., Minthon L., Zetterberg H., Vanmechelen E., Blennow K., Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J. Alzheimer's Dis. 2010, 21:1119-1128.
3. Hampel H., Bürger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Möller H.J., Davies P., Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 2004, 61:95-102.
4. Schönknecht P., Pantel J., Kaiser E., Thomann P., Schröder J. Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neurosci. Lett. 2007, 416:39-42.
5. Schönknecht P., Pantel J., Werle E., Hartmann T., Essig M., Baudendistel K., Beyreuther K., Schröder J. Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease. Fortschr. Neurol. Psychiatry 2000, 68:439-446.
6. Cooper E.H. Neuron-specific enolase. Int. J. Biol. Markers 1999, 9:205-210.
7. Kaiser E., Kuzmits R., Pregant P., Burghuber O., Worofka W. Clinical biochemistry of neuron specific enolase. Clin. Chim. Acta 1989, 183:13-31.
8. Pollak D., Cairns N., Lubec G. Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease. J. Neural. Transm. 2003, (Suppl.):149-158.
9. Duan P., Zhang Y., Han X., Liu J., Yan W., Xing Y. Effect of neuronal induction on NSE, Tau, and Oct4 promoter methylation in bone marrow mesenchymal stem cells. In Vitro Cell. Dev. Biol. Anim. 2012, 48:251-258.
10. Ahmad O., Wardlaw J., Whiteley W.N. Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc. Dis. 2012, 33:47-54.
11. Moritz S., Warnat J., Bele S., Graf B.M., Woertgen C. The prognostic value of NSE and S100B from serum and cerebrospinal fluid in patients with spontaneous subarachnoid hemorrhage. J. Neurosurg. Anesthesiol. 2010, 22:21-31.
12. Böhmer A.E., Oses J.P., Schmidt A.P., Perón C.S., Krebs C.L., Oppitz P.P., D'Avila T.T., Souza D.O., Portela L.V., Stefani M.A. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 2011, 68:1624-1630.
13. Hein Née Maier K., Köhler A., Diem R., Sättler M.B., Demmer I., Lange P., Bähr M., Otto M. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci. Lett. 2008, 436:72-76.
14. Palumbo B., Siepi D., Sabalich I., Tranfaglia C., Parnetti L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?. Funct. Neurol. 2008, 23:93-96.
15. Blennow K., Wallin A., Ekman R. Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders?. J. Neural Transm. Park. Dis. Dement. Sect. 1994, 8:183-191.
16. Parnetti L., Palumbo B., Cardinali L., Loreti F., Chionne F., Cecchetti R., Senin U. Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neurosci. Lett. 1995, 183:43-45.
17. Nooijen P.T., Schoonderwaldt H.C., Wevers R.A., Hommes O.R., Lamers K.J. Neuron-specific enolase. S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement. Geriatr. Cogn. Disord. 1997, 8:169-173.
18. Sulkava R., Viinikka L., Erkinjuntti T., Roine R. Cerebrospinal fluid neuron-specific enolase is decreased in multi-infarct dementia, but unchanged in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1988, 51:549-551.
19. Cutler N.R., Kay A.D., Marangos P.J., Burg C. Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer's disease. Arch. Neurol. 1986, 43:153-154.
20. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
21. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders (SCID I) 1997, Biometric Research Department, New York.
22. Burkart M., Heun R., Maier W., Benkert O. Dementia screening in routine clinical practice. A comparative analysis of MMSE, SIDAM and ADAS. Nervenarzt 1998, 69:983-990.
23. Henderson A.R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann. Clin. Biochem. 1993, 30:521-539.
24. Youden W.J. Index for rating diagnostic tests. Cancer 1950, 3:32-35.
25. Bendlin B.B., Carlsson C.M., Johnson S.C., Zetterberg H., Blennow K., Willette A.A., Okonkwo O.C., Sodhi A., Ries M.L., Birdsill A.C., Alexander A.L., Rowley H.A., Puglielli L., Asthana S., Sager M.A. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One 2012, 7:e37720.
26. Baig S., Palmer L.E., Owen M.J., Williams J., Kehoe P.G., Love S. Clusterin mRNA and protein in Alzheimer's disease. J. Alzheimers Dis. 2012, 28:337-344.
27. Harada H., Tamaoka A., Ishii K., Shoji S., Kametaka S., Kametani F., Saito Y., Murayama S. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci. Res. 2006, 54:24-29.
28. Constantinescu R., Zetterberg H., Holmberg B., Rosengren L. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat. Disord. 2009, 15:205-212.
29. Leem Y.H., Lee Y.I., Son H.J., Lee S.H. Chronic exercise ameliorates the neuroinflammation in mice carrying NSE/htau23. Biochem. Biophys. Res. Commun. 2011, 406:359-365.
30. Lee Y.J., Kim J.E., Hwang I.S., Kwak M.H., Lee J.H., Jung Y.J., An B.S., Kwon H.S., Kim B.C., Kim S.J., Kim J.M., Hwang D.Y. Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism. Mol. Med. Rep. 2013, 7:1571-1578.
31. Ramont L., Thoannes H., Volondat A., Chastang F., Millet M.C., Maquart F.X. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin. Chem. Lab. Med. 2005, 43:1215-1217.
32. Casmiro M., Maitan S., De Pasquale F., Cova V., Scarpa E., Vignatelli L., NSE Study Group Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur. J. Neurol. 2005, 12:369-374.
33. Lamers K.J., Vos P., Verbeek M.M., Rosmalen F., van Geel W.J., van B.G., Engelen Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 2003, 61:261-264.
34. Vanderstichele H., Bibl M., Engelborghs S., Le Bastard N., Lewczuk P., Molinuevo J.L., Parnetti L., Perret-Liaudet A., Shaw L.M., Teunissen C., Wouters D., Blennow K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's Dement. 2012, 8:65-73.